Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TLSI

TriSalus Life Sciences Inc

Dec 11 • 04:00PM ET

3.85

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Medical Devices • USA • NASD

Peers: CRSP NTLA FATE IMTX EDIT BLUE SGMO ADAP CELU SLDB

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.50	Insider Own	91.02%	Shs Outstand	30.47M	Perf Week	-6.55%
Market Cap	117.40M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	0.13%	Shs Float	3.81M	Perf Month	-14.06%
Income	-58.66M	PEG	-	EPS next Q	-0.31	Inst Own	7.12%	Short Float	1.23%	Perf Quarter	-25.10%
Sales	26.89M	P/S	4.37	EPS this Y	81.22%	Inst Trans	9.85%	Short Ratio	1.11	Perf Half Y	-36.15%
Book/sh	-0.67	P/B	-	EPS next Y	59.64%	ROA	-181.74%	Short Interest	0.05M	Perf Year	-23.15%
Cash/sh	0.37	P/C	10.40	EPS next 5Y	-	ROE	-2.48%	52W Range	3.50 - 10.42	Perf YTD	-54.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-2133.24%	52W High	-63.05%	Beta	0.58
Dividend TTM	-	Quick Ratio	2.00	Sales past 5Y	16.44%	Gross Margin	84.30%	52W Low	10.00%	ATR (14)	0.41
Dividend Ex-Date	-	Current Ratio	2.40	EPS Y/Y TTM	-609.71%	Oper. Margin	-158.85%	RSI (14)	43.56	Volatility	13.14% 10.70%
Employees	112	Debt/Eq	-	Sales Y/Y TTM	417.83%	Profit Margin	-218.15%	Recom	1.00	Target Price	11.92
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	8.76%	Payout	-	Rel Volume	0.90	Prev Close	3.85
Sales Surprise	-0.39%	EPS Surprise	65.39%	Sales Q/Q	41.52%	Earnings	Nov 14 BMO	Avg Volume	42.35K	Price	3.85
SMA20	-8.09%	SMA50	-8.52%	SMA200	-40.67%	Trades		Volume	38,238	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
04:05PM	Loading…
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
12:53PM	Loading…
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	Loading…
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67% +5.82%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)
Feb-21-23 07:00AM	TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business (Business Wire)
Dec-07-22 09:26PM	MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders (GlobeNewswire)
Nov-14-22 04:24PM	Colorado biotech company to go public via SPAC merger (American City Business Journals)
Mar-14-22 02:32PM	Robotic surgery company Memic pulls out of SPAC merger (American City Business Journals)
Mar-10-22 08:11AM	MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination (GlobeNewswire)
Jan-06-22 08:00AM	Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021 (PR Newswire)
Dec-30-21 03:00PM	A look at the South Florida tech companies that were acquired or went public in 2021 (American City Business Journals)
Oct-07-21 09:16AM	Is MedTech Acquisition Corporation (NASDAQ:MTAC) Popular Amongst Institutions? (Simply Wall St.)
Sep-09-21 06:00AM	Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation (PR Newswire)
Sep-03-21 09:25AM	Moore Kuehn Encourages FRSG, MTAC, SLCR, and ADF Investors to Contact Law Firm (GlobeNewswire)
Aug-19-21 12:32PM	Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal (PR Newswire)
Aug-13-21 05:49PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of MedTech Acquisition Corporation (Nasdaq - MTAC) (ACCESSWIRE)
08:07AM	Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination (PR Newswire)
Jun-02-21 04:05PM	MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-19-21 01:02PM	Robotics Firm Memic Is in Talks to Go Public Via SPAC (Bloomberg)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arjun Desai	Board of Directors	Dec 10 '24	Proposed Sale	4.50	30,000	135,000		Dec 10 04:06 PM
Wahlstrom Mats	Director	Nov 22 '24	Buy	4.55	5,000	22,750	15,727	Nov 25 05:53 PM
Wahlstrom Mats	Director	Nov 21 '24	Buy	4.44	8,687	38,570	10,727	Nov 22 07:11 PM
Wahlstrom Mats	Director	Nov 20 '24	Buy	4.16	2,040	8,486	2,040	Nov 22 07:11 PM
Szela Mary T	CEO AND PRESIDENT	Sep 12 '24	Buy	5.20	7,520	39,104	377,382	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 13 '24	Buy	4.97	7,295	36,255	384,677	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 10 '24	Buy	4.97	5,000	24,850	369,862	Sep 12 07:06 PM
Martin George Kelly	Director	Aug 28 '24	Sale	5.50	9	50	247,176	Sep 10 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience